Publication | Open Access

First-line bevacizumab plus taxane-based chemotherapy for locally recurrent or metastatic breast cancer: safety and efficacy in an open-label study in 2251 patients

Metastatic Breast CancerBreast OncologyFirst-line BevacizumabMedicinePathologyBreast CancerTaxane-based ChemotherapyAnti-cancer AgentCancer TreatmentOncologyRadiation OncologyMolecular Oncology